When Andreas Forsland’s mother was intubated in the ICU, she remained fully conscious but lost the ability to speak, leading to tremendous breakdowns in communication with her care providers.
Table of Contents
- Key Takeaways
- Launching the Vision Pro BCI Clinical Trial
- Cognixion’s Approach: Noninvasive BCI Versus Invasive Implants
- Targeting Severe Speech Impairments: Trial Participants and Conditions
- Integrating Generative AI with the Vision Pro Platform
- The Drive to Democratize Access and Adoption
- Conclusion: Expanding Communication Possibilities
This profound personal experience spurred Forsland to think critically about how individuals with speech motor disabilities urgently needed better communication methods.
Now, the company Forsland founded, Cognixion, announced a new initiative on October 1, 2025, launching a clinical trial that aims to translate the thoughts of paralyzed individuals into commands using cutting-edge wearable technology.
Key Takeaways
- California-based Cognixion is launching a clinical trial integrating its wearable BCI technology with a modified Apple Vision Pro headset.
- The BCI is noninvasive, utilizing a custom headband and augmented reality app, contrasting significantly with invasive solutions developed by companies like Neuralink.
- The trial targets up to 10 paralyzed participants in the US suffering from speech disorders due to conditions like ALS, stroke, or spinal cord injury.
- Cognixion previously tested its proprietary Axon-R headset, enabling patients to “speak” near normal conversation speed using custom generative AI software.
Launching the Vision Pro BCI Clinical Trial
Startup Cognixion announced today that it is launching a clinical trial integrating its wearable brain-computer interface (BCI) technology with the Apple Vision Pro headset.

The California-based company aims to help paralyzed people with speech disorders communicate using only their thoughts, bypassing the need for an invasive brain implant.
Cognixion will conduct these trials using a modified version of the Apple Vision Pro headset to test the effectiveness and usability of their system in a real-world setting.
This initiative focuses on translating captured brain signals into commands that control external devices. While Apple opened the door to BCI integration in May, the current trial marks a major step in applying augmented reality hardware to critical medical communication needs.
The goal is to successfully allow paralyzed patients to communicate without the surgical risks associated with implanted devices, setting a new precedent for the application of Vision Pro BCI systems in medical settings, according to the original article.
Cognixion’s Approach: Noninvasive BCI Versus Invasive Implants
Cognixion is developing a brain-computer interface (BCI) system alongside other prominent companies, including Elon Musk’s Neuralink. However, the Santa Barbara, California, company distinguishes itself by developing technology that remains noninvasive.
This approach contrasts sharply with competitors who are working on implants that require surgical placement in the head to capture brain signals.
Cognixion’s noninvasive Vision Pro BCI technology consists of two primary components being tested in the clinical trial. The first is a hardware add-on: a custom headband specifically designed to read the necessary brain signals.
The second is a software component, an augmented reality BCI app that translates those signals into actionable communication. The focus on a noninvasive solution is central to the company’s mission to maximize patient acceptance and reduce risk.
Targeting Severe Speech Impairments: Trial Participants and Conditions
The clinical trial will include up to 10 participants located within the US who suffer from speech impairments related to paralysis. Cognixion specifically seeks individuals whose paralysis resulted from severe conditions like spinal cord injury, stroke, or traumatic brain injury.
Furthermore, participants with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, are included in the study.
These participants represent populations who experience tremendous communication barriers due to motor disabilities.
By testing the Vision Pro BCI with this diverse group, Cognixion aims to validate that its system can consistently capture brain signals and translate them into usable commands across various neurological disorders.
Success in this trial would demonstrate the BCI’s viability as a generalizable communication tool for those unable to speak.
Integrating Generative AI with the Vision Pro Platform
Prior to integrating with the Apple Vision Pro, Cognixion successfully tested its own specialized headset, the Axon-R, with ALS patients earlier this year.
That proprietary technology used custom software that leveraged generative AI models, which trained on an individual user’s unique speech patterns.
This combination of hardware and AI enabled participants to communicate, or “speak,” through the headset at a rate that approached normal conversation speed.
That earlier study showed that patients could comfortably use the BCI technology for a few hours a day, several times a week. Now, Cognixion is transferring its AI communication app to the Vision Pro.
CEO Andreas Forsland notes the advantage of this shift, explaining that “The Vision Pro gives you all of your apps, the app store, everything you want to do,” offering more functionality than the purpose-built Axon-R headset.
The Drive to Democratize Access and Adoption
Cognixion’s overarching goal is to make BCI technology accessible to the largest number of people possible. The company views the Vision Pro as a critical avenue for achieving this widespread adoption.
Andreas Forsland, who started the company after witnessing the communication struggles his mother faced, emphasizes the importance of minimizing hurdles for users.
Forsland states that in order to democratize access, developers need to implement the technology “in such a way that’s the least risky and the most acceptable for adoption for the majority of people.” By offering a noninvasive solution integrated into a widely available platform like the Vision Pro, Cognixion bypasses the substantial risks and psychological barriers associated with invasive surgery, thus promoting greater acceptance of the Vision Pro BCI for essential communication, .
Conclusion: Expanding Communication Possibilities
The clinical trial announced by Cognixion represents a significant move toward deploying advanced BCI systems through consumer-grade hardware like the Apple Vision Pro.
By focusing on a noninvasive solution—combining a custom headband and an AR app—Cognixion directly addresses the high risk and low acceptance rates typical of surgically implanted technologies.
The company’s prior success with the Axon-R headset, which facilitated communication at near-normal speeds using generative AI, provides a strong foundation for the new Vision Pro BCI integration.
Ultimately, this trial aims to expand communication possibilities for patients paralyzed by ALS, stroke, and other severe conditions. CEO Andreas Forsland founded the company based on the critical need for reliable communication access.
Specifically, by selecting the Vision Pro, which offers a robust platform and wider functionality, Cognixion increases the likelihood of democratizing BCI technology, making thought-to-speech communication a viable, safe option for the majority of those who need it most.
| Latest From Us
- Forget Towers: Verizon and AST SpaceMobile Are Launching Cellular Service From Space

- This $1,600 Graphics Card Can Now Run $30,000 AI Models, Thanks to Huawei

- The Global AI Safety Train Leaves the Station: Is the U.S. Already Too Late?

- The AI Breakthrough That Solves Sparse Data: Meet the Interpolating Neural Network

- The AI Advantage: Why Defenders Must Adopt Claude to Secure Digital Infrastructure


